Gauthier Loron

Dr. Gauthier Loron

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2012 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AKAngela M. Kaindl
Angela M. Kaindl
VDVincent Degos
Vincent Degos
SPStéphane Peineau
Stéphane Peineau
EGElodie Gouadon
Elodie Gouadon
VCVibol Chhor
Vibol Chhor
PGPierre Gressens
Pierre Gressens

22 September 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
POPaul Olivier
Paul Olivier
RFRomain H. Fontaine
Romain H. Fontaine
GLGauthier Loron
Gauthier Loron
JSJuliette Van Steenwinckel
Juliette Van Steenwinckel
VBValérie Biran
Valérie Biran
OBOlivier Baud
Olivier Baud
To investigate the effects of melatonin treatment in a rat model of white matter damage (WMD) in the developing brain. Additionally, we aim to delineate the cellular mechanisms of melatonin effect on the oligodendroglial cell lineage. A unilateral ligation of the uterine artery in pregnant rat at the embryonic day 17 induces fetal hypoxia and subsequent growth restriction (GR) in neonatal pups. GR and control pups received a daily intra-peritoneal injection of melatonin from birth to post-natal day (P) 3. Melatonin administration was associated with a dramatic decrease in microglial activation and astroglial reaction compared to untreated GR pups. At P14, melatonin prevented white matter myelination defects with an increased number of mature oligodendrocytes (APC-immunoreactive) in treated GR pups. Conversely, melatonin was not found to be associated with an increased density of total oligodendrocytes (Olig2-immunoreactive), suggesting that melatonin is able to promote oligodendrocyte maturation but not proliferation. These effects appear to be melatonin-receptor dependent and were reproduced in vitro. These data suggest that melatonin has a strong protective effect on developing damaged white matter through decreased microglial activation and oligodendroglial maturation leading to a normalization of the myelination process. Consequently, melatonin should be a considered as an effective neuroprotective candidate not only in perinatal brain damage but also in inflammatory and demyelinating diseases observed in adults.

13 June 2008 in Cell Death & Differentiation
Verified
Journal Article
Closed access
RFR H Fontaine
R H Fontaine
OCO Cases
O Cases
VLV Lelièvre
V Lelièvre
BMB Mesplès
B Mesplès
JRJ-C Renauld
J-C Renauld
PGPierre Gressens
Pierre Gressens

15 December 2011 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
NBNathalie Bednarek
Nathalie Bednarek
PSPernilla Svedin
Pernilla Svedin
RGRoselyne Garnotel
Roselyne Garnotel
GERALDINE FAVRAISGERALDINE FAVRAIS
GERALDINE FAVRAIS
GLGauthier Loron
Gauthier Loron
PGPierre Gressens
Pierre Gressens

1 June 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JPJulien Pansiot
Julien Pansiot
GLGauthier Loron
Gauthier Loron
POPaul Olivier
Paul Olivier
RFRomain Fontaine
Romain Fontaine
CCChristiane Charriaut-Marlangue
Christiane Charriaut-Marlangue
OBOlivier Baud
Olivier Baud
Inhaled nitric oxide (iNO) is one of the most promising therapies used in neonates. However, little information is known about its impact on the developing brain submitted to excitotoxic challenge. We investigated here the effect of iNO in a neonatal model of excitotoxic brain lesions. Rat pups and their dams were placed in a chamber containing 20 ppm NO during the first week of life. At postnatal day (P)5, rat pups were submitted to intracranial injection of glutamate agonists. At P10, rat pups exposed to iNO exhibited a significant decrease of lesion size in both the white matter and cortical plate compared to controls. Microglia activation and astrogliosis were found significantly decreased in NO-exposed animals. This neuroprotective effect was associated with a significant decrease of several glutamate receptor subunits expression at P5. iNO was associated with an early (P1) downregulation of pCREB/pAkt expression and induced an increase in pAkt protein concentration in response to excitotoxic challenge (P7). This study is the first describe and investigate the neuroprotective effect of iNO in neonatal excitotoxic-induced brain damage. This effect may be mediated through CREB pathway and subsequent modulation of glutamate receptor subunits expression.

1 June 2008 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
VDVincent Degos
Vincent Degos
GLGauthier Loron
Gauthier Loron
JMJean Mantz
Jean Mantz
PGPierre Gressens
Pierre Gressens
Injury to the perinatal brain is a leading cause of childhood mortality and lifelong disability. Cerebral palsy and cognitive impairment are usually related to periventricular white matter damage, which is seen chiefly in babies born before 32 wk gestational age, and to corticosubcortical lesions, which occur mainly in full-term infants. Despite recent improvements in neonatal care, no effective treatment for perinatal brain lesions is available. Several interventions, such as magnesium sulfate in preterm newborns and hypothermia in term newborns, are the focus of completed or continuing clinical trials. Improved understanding of the pathophysiological mechanisms involved in perinatal brain lesions helps to identify potential targets for neuroprotective interventions, as discussed in this review.